Cargando…

CAR-T Therapy in GBM: Current Challenges and Avenues for Improvement

SIMPLE SUMMARY: Clinical trials in glioblastoma (GBM) using CAR-T cells have not yielded tangible results. However, clinical and immunological observations from the trials have provided key insights into ways to limit toxicities and extend the antitumor efficacy of CAR-T cells. Incorporating recent...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pant, Ayush, Lim, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954019/ https://www.ncbi.nlm.nih.gov/pubmed/36831591 http://dx.doi.org/10.3390/cancers15041249

Ejemplares similares

SYST-32 A NOVEL APPROACH TO TARGET TREG-MEDIATED IMMUNOSUPPRESSION IN GBM
por: Pant, Ayush, et al.
Publicado: (2023)

iNKT: A new avenue for CAR-based cancer immunotherapy
por: Liu, Yilin, et al.
Publicado: (2022)

CAR T cell therapy and the tumor microenvironment: Current challenges and opportunities
por: Kankeu Fonkoua, Lionel A., et al.
Publicado: (2022)

The Road to CAR T-Cell Therapies for Pediatric CNS Tumors: Obstacles and New Avenues
por: Burns, Ian, et al.
Publicado: (2022)

CAR T-Cell Therapy for Patients with Multiple Myeloma: Current Evidence and Challenges
por: Rendo, Matthew J, et al.
Publicado: (2022)

Randomized Controlled Immunotherapy Clinical Trials for GBM Challenged
por: Van Gool, Stefaan W., et al.
Publicado: (2020)

CAR T Cell Therapy: Remedies of Current Challenges in Design, Injection, Infiltration and Working
por: Zhu, Yuxuan, et al.
Publicado: (2023)

Mechanisms of Resistance and Current Treatment Options for Glioblastoma Multiforme (GBM)
por: Yalamarty, Satya Siva Kishan, et al.
Publicado: (2023)

Using Light for Therapy of Glioblastoma Multiforme (GBM)
por: Vasilev, Alex, et al.
Publicado: (2020)

The challenge of finding new therapeutic avenues in soft tissue sarcomas
por: Kasper, Bernd
Publicado: (2019)

CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges
por: Zhang, Xiaomin, et al.
Publicado: (2022)

CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances
por: Maalej, Karama Makni, et al.
Publicado: (2023)

Challenges of Anti-Mesothelin CAR-T-Cell Therapy
por: Zhai, Xuejia, et al.
Publicado: (2023)

Custom CARs: Leveraging the Adaptability of Allogeneic CAR Therapies to Address Current Challenges in Relapsed/Refractory DLBCL
por: Jeyakumar, Nikeshan, et al.
Publicado: (2022)

Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany
por: Albinger, Nawid, et al.
Publicado: (2021)

Quantitative Epigenetics: A New Avenue for Crop Improvement
por: Gahlaut, Vijay, et al.
Publicado: (2020)

Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment
por: Yan, Ting, et al.
Publicado: (2023)

Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion
por: Gumber, Diana, et al.
Publicado: (2022)

New Avenues for Nanoparticle-Related Therapies
por: Zhao, Michael, et al.
Publicado: (2018)

Metabolism as a New Avenue for Hepatocellular Carcinoma Therapy
por: Gnocchi, Davide, et al.
Publicado: (2023)

Current Progress in CAR-T Cell Therapy for Solid Tumors
por: Ma, Shuo, et al.
Publicado: (2019)

Current Progress in CAR-T Cell Therapy for Hematological Malignancies
por: Han, Donglei, et al.
Publicado: (2021)

Current progress in CAR-T cell therapy for tumor treatment
por: Chen, Lei, et al.
Publicado: (2022)

Current Progress of CAR-NK Therapy in Cancer Treatment
por: Pang, Zhaojun, et al.
Publicado: (2022)

The role of neurosurgery in medulla oblongata GBM, a challenge
por: Fahlbusch, Rudolf
Publicado: (2019)

Current review of in vivo GBM rodent models: emphasis on the CNS-1 tumour model
por: Jacobs, Valerie L, et al.
Publicado: (2011)

Advances in co-opting anti-depressant drugs in glioma therapy
por: Pant, Ayush, et al.
Publicado: (2022)

Expanding Avenue of Fast Neutron Mediated Mutagenesis for Crop Improvement
por: Kumawat, Surbhi, et al.
Publicado: (2019)

2-Cell-like Cells: An Avenue for Improving SCNT Efficiency
por: Fu, Bo, et al.
Publicado: (2022)

Preclinical Models and Technologies in Glioblastoma Research: Evolution, Current State, and Future Avenues
por: Slika, Hasan, et al.
Publicado: (2023)

The Role of Myeloid Cells in GBM Immunosuppression
por: Lin, Ya-Jui, et al.
Publicado: (2022)

Current Opinion on Molecular Characterization for GBM Classification in Guiding Clinical Diagnosis, Prognosis, and Therapy
por: Zhang, Pei, et al.
Publicado: (2020)

Innovative CAR-T Cell Therapy for Solid Tumor; Current Duel between CAR-T Spear and Tumor Shield
por: Jo, Yuna, et al.
Publicado: (2020)

CAR-T cell therapy: current limitations and potential strategies
por: Sterner, Robert C., et al.
Publicado: (2021)

Current status and hurdles for CAR-T cell immune therapy
por: Zhao, Ruocong, et al.
Publicado: (2019)

Challenges and optimal strategies of CAR T therapy for hematological malignancies
por: Zhang, Yajing, et al.
Publicado: (2023)

Mitochondrial DNA Alterations in Glioblastoma (GBM)
por: Leão Barros, Mariceli Baia, et al.
Publicado: (2021)

Engineering Adenoviral Vectors with Improved GBM Selectivity
por: Bates, Emily A., et al.
Publicado: (2023)

Current State of CAR T-Cell Therapy in Chronic Lymphocytic Leukemia
por: Mancikova, Veronika, et al.
Publicado: (2021)

The application of CAR-T cell therapy in hematological malignancies: advantages and challenges
por: Zhao, Zijun, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_3ojso10crk133skf54nil2l25n